Zenas BioPharma says Phase 3 INDIGO extension shows 0.93 12-month flare-free probability for obexelimab in IgG4-RD

• Zenas Biopharma disclosed new Phase 3 INDIGO open-label extension results for obexelimab in IgG4-related disease, already presented Oct. 8-10, 2026.
• Longer-term data showed patients largely stayed flare-free on continued treatment, with a safety profile consistent with earlier study experience.
• A separate analysis found obexelimab reduced steroid-related toxicity versus placebo over the controlled study period, supporting a steroid-sparing positioning.
• Early sub-study readouts indicated patients mounted influenza and COVID-19 vaccine responses during a planned treatment-free window without triggering disease flares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120700PRIMZONEFULLFEED9843626) on October 12, 2026, and is solely responsible for the information contained therein.